About Keel

Keel Pharmaceuticals, Inc. is an emerging biopharmaceutical company that is developing new therapies for treating type 1 diabetes, lupus, scleroderma and other autoimmune diseases.  Keel’s technology is based on the identification of specific protein processing and signaling defects in the autoreactive lymphocytes (T, B and other white blood cells) that cause autoimmune disease.  The identification of these defects has yielded a proprietary approach to the treatment of autoimmunity based on selective destruction of lymphocytes responsible for autoimmune reactions.  Keel believes that its approach offers a promising opportunity to treat the underlying causes of these devastating diseases without interfering with the normal functioning of a patient’s immune system.  Keel believes that its drugs, once developed, will exhibit greater specificity and fewer side effects than drugs currently on the market or under development for the treatment of autoimmunity.